Скачать или смотреть Advancing Small Nucleic Acid Drug Development with a One-Stop Solution

Speaker: Mark Shulewitz, PhD, Field Application Scientist – Life Science Group, GenScript Biotech Corporation

Abstract:
Small nucleic acid drugs, such as siRNA, anti-sense oligonucleotides (ASO), miRNA and aptamers, function by binding to and inhibit the activity of RNA through a process known as RNA interference (RNAi).
This class of molecules offer many advantages over traditional pharmaceuticals: unlimited target selection, high specificity, long half-life, ease of design and fast development and production processes. In this webinar, the expert speaker will discuss recent advances in the development of small nucleic acid drugs and explain how a one-stop solution from design and synthesis to analysis, screening, verification and delivery can accelerate research.